Health Boards
Sun-24-04-2016, 21:31 PM
Read this in the monthly paper of Sanquin.
Sanquin, Dutch blood institute, participates in a British consortium, PSORT, Psoriasis Stratification to Optimize Relevant Therapy. Dermatologists, researchers, pharmaceutical organisations but also patients are here in United to try to Optimize the therapy with biologicals. The consortium received 5 million pounds in 2013 from the English medical research council and another 2 million of the industrial partners.
People with serious forms of psoriasis benefit from the treatment with biologicals. This new class of medication is very expensive, estimated costs 15.000 per patient per year. Unfortunately part of the patients does not respond well. Possible reasons are genetic background, too low medication levels because of metabolic variations of the forming of antibodies against the medication. PSORT strives for personalised treatment, that holds this and other factors into account.
This results in optimal clinical results, but also in insight in other less common immune diseases as well as a cost reduction in health care.
With the division research, dr. Karien Bloem and dr. Theo Rispens are involved with PSORT. And From diagnostics dr. Annick de Vries with her biologicals lab. Direct corporation in Great Britain is going via doctor-researchers from the Kings College in London and from the university of Manchester. "We are very happy that we found a lab that is able to measure medication as well as anti-drug antibodies combined with the expertise of Sanquin Research on the area of immunogenicity. Together with other parameter that we study with the consortium these tests are an easy and cheap way to support personalised medication". Sanquin is busy developing a blood-spot technique for PSORT so patients can take their blood at home and inform their consultant for adjusting the personalised treatment.
Sanquin, Dutch blood institute, participates in a British consortium, PSORT, Psoriasis Stratification to Optimize Relevant Therapy. Dermatologists, researchers, pharmaceutical organisations but also patients are here in United to try to Optimize the therapy with biologicals. The consortium received 5 million pounds in 2013 from the English medical research council and another 2 million of the industrial partners.
People with serious forms of psoriasis benefit from the treatment with biologicals. This new class of medication is very expensive, estimated costs 15.000 per patient per year. Unfortunately part of the patients does not respond well. Possible reasons are genetic background, too low medication levels because of metabolic variations of the forming of antibodies against the medication. PSORT strives for personalised treatment, that holds this and other factors into account.
This results in optimal clinical results, but also in insight in other less common immune diseases as well as a cost reduction in health care.
With the division research, dr. Karien Bloem and dr. Theo Rispens are involved with PSORT. And From diagnostics dr. Annick de Vries with her biologicals lab. Direct corporation in Great Britain is going via doctor-researchers from the Kings College in London and from the university of Manchester. "We are very happy that we found a lab that is able to measure medication as well as anti-drug antibodies combined with the expertise of Sanquin Research on the area of immunogenicity. Together with other parameter that we study with the consortium these tests are an easy and cheap way to support personalised medication". Sanquin is busy developing a blood-spot technique for PSORT so patients can take their blood at home and inform their consultant for adjusting the personalised treatment.